Phyllocontin® (aminophylline) Continus 225mg and Phyllocontin® Forte Continus 350mg modified-release tablets are being discontinued in the UK.
Remaining supplies of the 225mg strength are expected to be exhausted by 2nd March 2021 and the 350mg strength are expected to be exhausted by 5th April 2021.
Phyllocontin® (aminophylline) is used in adults for the treatment and prophylaxis of bronchospasm associated with asthma, chronic obstructive pulmonary disease and chronic bronchitis. For children, it is used for the management of asthma.
Prescribers will need to review all affected patients and optimise inhaled therapies. Patients who still require a methylxanthine, will need to be switched to theophylline tablets (Uniphyllin Continus®).
This alert contains further information and action for providers.
Please note that no response is required via the CAS website to this alert.